 Abbott Laboratories said it would sell a portion of its generics pharmaceuticals business to Mylan Inc. in an all-stock transaction valued at $5.3 billion that is the latest example of a health-care deal driven in part to seek tax advantages.. Abbott will receive about a 21% stake, or 105 million shares, of a newly formed entity that will combine Mylan's existing business and Abbott's generic pharmaceuticals business in developed markets not including the U.S. The new entity will be organized in the Netherlands, enabling the...
  